Alterity’s QSM MRI Distinguishes MSA from PD with AUC 0.76–0.79
Alterity Therapeutics published a NeuroImage study showing QSM MRI detected significantly elevated iron in the lentiform nucleus of MSA patients versus healthy controls and Parkinson’s disease (AUC 0.76–0.79). Iron levels correlated with Unified Multiple System Atrophy Rating Scale severity and increased over 12 months, validating QSM as a biomarker for ATH434 trials.
1. Study Overview
Alterity’s team and collaborators analyzed high-resolution QSM and structural MRI data from 10 MSA patients followed for 12 months, alongside cross-sectional data from 28 MSA, 43 Parkinson’s disease and 23 healthy controls. The publication outlines methods for quantifying regional brain iron and tracking progression in early-stage MSA.
2. Key Findings
MSA patients showed significantly higher iron content in the globus pallidus and putamen versus controls and Parkinson’s disease (all p<0.05), with globus pallidus iron distinguishing MSA from PD at an AUC of 0.76–0.79. Iron burden correlated strongly with UMSARS scores, and longitudinal data revealed progressive iron accumulation over 12 months.
3. Biomarker Validation and ATH434 Impact
QSM imaging was implemented in Alterity’s Phase 2 ATH434 trial, enhancing diagnostic accuracy and providing objective evidence of target engagement. These results validate QSM as an imaging biomarker to support earlier diagnosis and monitor iron-modulating therapy effects in future ATH434 studies.
4. Development and Regulatory Outlook
Alterity is advancing ATH434 into Phase 3 for MSA, having secured positive FDA feedback on clinical pharmacology, non-clinical development and CMC elements. The company aims to hold its End-of-Phase 2 meeting in mid-2026 as a precursor to initiating a pivotal Phase 3 trial.